2022 Pivotal Points, Currents, and Controversies in nr-axSpA: What You May Have Missed




This activity is provided by Integrity Continuing Education, Inc.


This activity is supported by an educational grant from AbbVie Inc.


Axial spondyloarthritis (axSpA) is now thought to be a disease continuum from early, nonradiographic disease (nr-axSpA), to more advanced disease that is easily detectable by radiograph (r-axSpA, better known as ankylosing spondyloarthritis [AS]). However, these delineations are not clear cut and not without controversy.

In 2022, the nuances of the axSpA disease spectrum began to take firmer definition as experts in this rheumatologic disorder offered greater clarity toward arriving at consensus on how to detect nr-axSpA and differentiate between it and r-axSpA/AS. Additionally, 3 biologics and 1 janus kinase (JAK) inhibitor were approved by the FDA in 2022 specifically for the treatment of nr-axSpA.

Join axSpA expert Dr. Atul Deodhar to find out what rheumatologists and other healthcare professionals who care for patients with axSpA need to know about how to evaluate nr-axSpA and what to know about the new and emerging treatments that are designed specifically for nr-axSpA.


Atul Deodhar, MD
Professor of Medicine
Medical Director, Rheumatology Clinics
Division of Arthritis and Rheumatic Diseases
Oregon Health and Science University
Portland, Oregon

Release date: January 4, 2023
Expiration date: January 4, 2024
Estimated time to complete activity: 45 minutes

This educational activity has been designed to meet the needs of rheumatologists, internal medicine physicians, and other clinicians who manage patients with nr-axSpA, including rheumatology-specialist nurse practitioners and physician assistants.


Upon completion of this educational activity, participants should be able to:

  • Review published data that define nr-axSpA within the axSpA disease continuum to facilitate more timely diagnoses
  • Incorporate recently approved or emerging biologic and small-molecule treatments for appropriately selected patients with nr-axSpA, based on efficacy and safety data from clinical trials

There are no fees for participating and receiving CME credit for this activity. During the period of January 4, 2023 through January 4, 2024, participants must:

  • Read the learning objectives
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Atul Deodhar, MD
Advisory Boards: AbbVie, Eli Lilly, Janssen/UCB, Novartis
Consultant: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen/UCB, MoonLake, Novartis
Research Grants: Bristol Myers Squibb, Celgene, Eli Lilly, Janssen/UCB, MoonLake, Novartis
Speaker: Janssen/UCB

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest